Ibrutinib and Venetoclax for First-Line Treatment of CLL

被引：15
|
作者：
Kater, Arnon P. [1 ]
Levin, Mark-David [2 ]
Niemann, Carsten U. [3 ]
机构：
[1] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[2] Albert Schweitzer Hosp, Dordrecht, Netherlands
[3] Rigshosp, Copenhagen, Denmark
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2019年 / 381卷 / 08期
关键词：
D O I：
10.1056/NEJMc1908754
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
To the Editor: In their phase 2 study, Jain et al. (May 30 issue)(1) investigated the efficacy of ibrutinib and venetoclax in previously untreated patients with chronic lymphocytic leukemia (CLL). Currently, it is unknown whether this combination is efficacious in patients with relapsed or refractory CLL. In the VISION/HOVON141 trial (ClinicalTrials.gov number, NCT03226301), we assessed the efficacy and safety of ibrutinib and venetoclax in patients with relapsed or refractory CLL. A preplanned interim analysis was performed after six cycles of full-dose ibrutinib and venetoclax in 51 patients. The overall response rate (according to International Workshop on Chronic Lymphocytic Leukemia [IWCLL] . . .
引用
收藏
页码：788 / 789
页数：2
相关论文
共 50 条
  • [1] Ibrutinib and Venetoclax for First-Line Treatment of CLL
    Jain, Nitin
    Keating, Michael
    Thompson, Philip
    Ferrajoli, Alessandra
    Burger, Jan
    Borthakur, Gautam
    Takahashi, Koichi
    Estrov, Zeev
    Fowler, Nathan
    Kadia, Tapan
    Konopleva, Marina
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney
    Bose, Prithviraj
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey
    Garg, Naveen
    Wang, Xuemei
    Sondermann, Katrina
    Cruz, Nichole
    Wei, Chongjuan
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop
    Gandhi, Varsha
    Wierda, William
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (22): : 2095 - 2103
  • [2] Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Burger, Jan A.
    Borthakur, Gautam M.
    Takahashi, Koichi
    Estrov, Zeev E.
    Fowler, Nathan H.
    Kadia, Tapan M.
    Konopleva, Marina Y.
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Bose, Prithviraj
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Sondermann, Katrina
    Cruz, Nichole
    Wei, Chongjuan
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop M.
    Gandhi, Varsha
    Wierda, William G.
    [J]. BLOOD, 2019, 134
  • [3] EHA 2023: New Results on Ibrutinib in Combination with Venetoclax in the First-line Treatment of CLL
    不详
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (10) : 447 - 447
  • [4] Similar outcomes regardless of post-randomization treatment with ibrutinib or ibrutinib plus venetoclax in the phase 2 CAPTIVATE study of first-line ibrutinib plus venetoclax in CLL
    Siddiqi, Tanya
    Tam, Constantine S.
    Wierda, William G.
    Ghia, Paolo
    Kipps, Thomas J.
    Tedeschi, Alessandra
    Gonzalez-Barca, Eva
    Szafer-Glusman, Edith
    Zhou, Cathy
    Neumayr, Lynne D.
    Allan, John N.
    [J]. CANCER RESEARCH, 2023, 83 (08)
  • [5] Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Burger, Jan A.
    Borthakur, Gautam
    Takahashi, Koichi
    Estrov, Zeev E.
    Sasaki, Koji
    Fowler, Nathan H.
    Kadia, Tapan M.
    Konopleva, Marina
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Bose, Prithviraj
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Wang, Wei
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Cruz, Nichole
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop M.
    Gandhi, Varsha
    Wierda, William G.
    [J]. BLOOD, 2020, 136
  • [6] Combination of ibrutinib and venetoclax in first-line treatment of chronic lymphocytic leukemia
    Stocker, Nicolas
    [J]. HEMATOLOGIE, 2022, 28 (01): : 12 - 13
  • [7] Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort
    Tam, Constantine S.
    Allan, John N.
    Siddiqi, Tanya
    Kipps, Thomas J.
    Jacobs, Ryan
    Opat, Stephen
    Barr, Paul M.
    Tedeschi, Alessandra
    Trentin, Livio
    Bannerji, Rajat
    Jackson, Sharon
    Kuss, Bryone J.
    Moreno, Carol
    Szafer-Glusman, Edith
    Russell, Kristin
    Zhou, Cathy
    Ninomoto, Joi
    Dean, James P.
    Wierda, William G.
    Ghia, Paolo
    [J]. BLOOD, 2022, 139 (22) : 3278 - 3289
  • [8] Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Burger, Jan A.
    Borthakur, Gautam
    Takahashi, Koichi
    Estrov, Zeev E.
    Sasaki, Koji
    Kadia, Tapan M.
    Konopleva, Marina
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Bose, Prithviraj
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias J.
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Wang, Wei
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Wei, Chongjuan
    Cruz, Nichole
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop
    Gandhi, Varsha
    Wierda, William G.
    [J]. BLOOD, 2021, 138 : 3720 - +
  • [9] Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL).
    Wierda, William G.
    Siddiqi, Tanya
    Flinn, Ian
    Badoux, Xavier C.
    Kipps, Thomas J.
    Allan, John N.
    Tedeschi, Alessandra
    Pagel, John M.
    Kuss, Bryone J.
    Barca, Eva Gonzalez
    Ghia, Paolo
    Eckert, Karl
    Zhou, Cathy
    Ninomoto, Joi
    Dean, James P.
    James, Danelle Frances
    Tam, Constantine
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] ASH 2022: Updated Results presented on the Ibrutinib and Venetoclax Combination Therapy in First-Line chronic lymphocytic Leukemia (CLL)
    Schoellmann, Claudia
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (1-2)
12345